LungBlog

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today presented positive results from a Phase 1b clinical trial of its lead product candidate obatoclax (GX15-070) for the treatment of first line patients with extensive-stage small cell lung cancer (SCLC).

Merck KGaA’s experimental cancer vaccine Stimuvax proved safe to use in a long-term Phase II study on lung cancer patients, the German drugmaker said on Saturday.

The trial showed that patients’ immune systems did not turn on normal cells, a major concern in new vaccines that are designed to prime the body’s immune system to detect and attack cancer cells.

Please join us and be a part of a great cause at the K&L and Bonnie J. Addario Lung Cancer Foundation (BJALCF) Charity Tasting. As one of the nation’s largest philanthropies devoted exclusively to eradicating lung cancer, BJALCF works with a diverse group of physicians, organizations and individuals to identify solutions and make timely and meaningful change through research, early detection, education, prevention, and treatment.

British scientists have developed the first blood test for lung cancer which could save thousands of lives. 

The revolutionary test picks up proteins in blood that are only produced as a reaction to the presence of lung cancer cells

Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, demonstrating that the addition of vandetanib to docetaxel resulted in a statistically significant improvement in progression-free survival (PFS), the length of time a patient lives without their cancer growing.

Lung cancer screenings may carry hidden dangers, researchers announced Saturday at the American Society of Clinical Oncologymeeting in Orlando.

People who are screened have a 21% chance of being unnecessarily frightened by findings that initially seem suspicious, but turn out to be benign, says lead author Jennifer Croswell.

There’s more troubling news about hormone therapy for menopause symptoms: Lung cancer seems more likely to prove fatal in women who are taking estrogen-progestin pills, a study suggests.

Hormone users who developed lung cancer were more than twice as likely to die from the disease as women who weren’t taking hormones, according to results reported Saturday.

Researchers plan to present new data this weekend confirming what many doctors have long suspected: Iressa, a lung-cancer drug once thought to be a flop, could actually be of use to tens of thousands of patients — specifically, to Asians, nonsmokers and others with a certain genetic quirk.

Lung Cancer Alliance (LCA) said that the American Cancer Society’s claim of “progress in cancer fight” earlier this week was based on “selective culling of statistics and ignores the dismal truth that we have made very little progress on the most lethal cancers, including lung cancer, which causes one in every two cancer deaths, or in metastatic cancer of any kind.”

Eli Lilly and Company announced today that the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA(R) (pemetrexed for injection) as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.